Dataset Information
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
Ontology highlight
ABSTRACT:
SUBMITTER: Kande Betu Ku Mesu V
PROVIDER: S-EPMC8220131 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature
Publications
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
The Lancet. Global health 20210701 7
<h4>Background</h4>Staging and treatment of human African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT) required lumbar puncture to assess cerebrospinal fluid (CSF) and intravenous drugs that cross the blood-brain barrier for late-stage infection. These procedures are inconvenient in rural health systems of disease-endemic countries. A pivotal study established fexinidazole as the first oral monotherapy to be effective against non-severe stage 2 g-HAT. We aimed to assess the saf ...[more]
